Elevated serum levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 in chronic heart failure patients with left ventricular hypertrophy

Elevated serum levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 in chronic heart failure patients with left ventricular hypertrophy

Hiromichi Wada1, Tomohide Takaya1,2, Tatsuya Morimoto3, Yoichi Sunagawa4, Masatoshi Fujita4, Takeshi Kimura2, Yoshiko Fujita5, Yuko Sato5, Akira Shimatsu6, Tatsuya Sawamura5, Koji Hasegawa2.

  1. Division of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  2. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  3. Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.
  4. Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  5. Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
  6. Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

World Congress of the International Society for Heart Research 2010 (Kyoto, Japan), 2010/05/16 (Poster).

Abstract

Background: Lectin-like oxidized low-density lipoprotein (oxLDL) receptor-1 (LOX-1) is now recognized as a multi-ligand receptor. Recently, we found that left ventricular (LV) expression of LOX-1 was markedly increased in the rat model of heart failure with LV hypertrophy (LVH). The extracellular domain of LOX-1 can be proteolytically cleaved and released into the blood stream in a soluble form (sLOX-1). However, the clinical significance of sLOX-1 in chronic heart failure (CHF) is unknown.

Methods and Results: We carried out a cross-sectional study including CHF patients with LVH (CHF-LVH) and apparently healthy subjects with normal LV dimensions and systolic function (control), and measured serum levels of sLOX-1. There were no significant differences in the age, body mass index, systolic and diastolic blood pressures, and heart rate between CHF-LVH and control groups. However, the LV end-diastolic dimension and LV mass index were significantly greater, and LV ejection fraction was significantly lower in the CHF-LVH than the control group. Interestingly, serum levels of sLOX-1 were significantly increased in the CHF-LVH compared to the control group.

Conclusion: These findings support the need for further investigations to assess the clinical utility and prognostic value of serum levels of sLOX-1 in patients with CHF.